Sphera Funds Management Ltd. Crinetics Pharmaceuticals, Inc. Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $9.02 Million - $12.4 Million	-588,897 Reduced 87.68%	82,747 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $698,475 - $859,002	45,092 Added 7.2%	671,644 $12.3 Million
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $719,546 - $888,804	39,732 Added 6.77%	626,552 $12.3 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $1.07 Million - $1.79 Million	64,873 Added 12.43%	586,820 $10.9 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $1.69 Million - $2.79 Million	98,699 Added 23.32%	521,947 $11.5 Million
Q4 2021 Feb 14, 2022	SELL	$19.35 - $28.41 $2.43 Million - $3.56 Million	-125,395 Reduced 22.86%	423,248 $12 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $1.44 Million - $2.16 Million	-85,445 Reduced 13.48%	548,643 $11.5 Million
Q2 2021 Aug 17, 2021	BUY	$15.9 - $21.15 $5.56 Million - $7.4 Million	349,864 Added 123.09%	634,088 $12 Million
Q1 2021 May 17, 2021	BUY	$13.3 - $17.55 $3.78 Million - $4.99 Million	284,224 New	284,224 $4.34 Million

243

80.1M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.11B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.